Japan Grants Orphan Drug Designation to Lynparza for Germline BRCA-mutated Pancreatic Cancer
Last week, AstraZeneca announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted its PARP inhibitor Lynparza (olaparib), an orphan drug designation for the maintenance treatment of germline …
Read More